Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | PRKCG | P05129 | 1/20 | 0.35 |
| ▸ | PRKCB | P05771 | 1/20 | 0.35 |
| ▸ | PRKCH | P24723 | 1/20 | 0.35 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 10/20 | 0.35 |
| ▸ | CNR1 | P21554 | 8/20 | 0.35 |
| ▸ | DAGLB | Q8NCG7 | 3/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LIPC | P11150 | 1/20 | 0.33 |
| ▸ | PNLIP | P16233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Antibiotic 1233A SCHEMBL285680 | 1.00 | PRKCA (0.35) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| Antibiotic 1233A SCHEMBL613745 | 1.00 | PRKCA (0.35) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL10371410 | 0.88 | PRKCA (0.35) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL713540 | 0.88 | PRKCA (0.35) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL10371408 | 0.88 | PRKCA (0.35) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL9659447 | 0.88 | DAGLA (0.35) | DAGLACNR1DAGLBMGLLMEN1 | |
| SCHEMBL713269 | 0.86 | DAGLA (0.34) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL713268 | 0.86 | DAGLA (0.34) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL9824730 | 0.85 | PRKCA (0.34) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL6061849 | 0.83 | PRKCA (0.40) | PRKCAPRKD3PRKCGPRKCBPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | METABASIS THERAPEUTICS INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS INC. | 2018-12-06 | — | — | US | disclosed |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170112864-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | METABASIS THERAPEUTICS, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| US-9102599-B2 | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-11 | — | — | US | disclosed |
| EP-2392567-B1 | BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8642576-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1088819-A2 | 6-azauracil derivatives as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-0944602-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023593-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | disclosed |
| EP-0293132-B1 | ANTIHYPERCHOLESTEROLEMIC BETA-LACTONES | MERCK & CO. INC. (US) | 1990-11-14 | — | — | EP | disclosed |
| EP-0349047-A2 | Treatment of diabetic ketoacidosis | MERCK & CO. INC. (US) | 1990-01-03 | — | — | EP | disclosed |
| US-4873260-A | B-LACTONE ALKYLENE CARBOXYLIC ACIDS AND DERIVATIVES | MERCK & CO., INC. (US) | 1989-10-10 | — | — | US | disclosed |
| US-4806564-A | Antihypercholesterolemic beta-lactones | MERCK & CO., INC. (US) | 1989-02-21 | — | — | US | disclosed |
| EP-0293132-A1 | Antihypercholesterolemic beta-lactones | MERCK & CO. INC. (US) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112864-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | TSHR, THRA, FABP1 | PRKCA 2319/4885PRKD3 1382/4885PRKCG 2268/4885 |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | THRB, THRA, TSHR | PRKCA 1588/4885PRKD3 1099/4885PRKCG 1610/4885 |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | PRKCA 2319/4885PRKD3 1382/4885PRKCG 2268/4885 |
| US-20190083515-A1 | THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES | TSHR, THRA, FABP1 | PRKCA 2320/4885PRKD3 1371/4885PRKCG 2262/4885 |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | PRKCA 1588/4885PRKD3 1099/4885PRKCG 1610/4885 |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | PRKCA 1588/4885PRKD3 1099/4885PRKCG 1610/4885 |
| US-10130643-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | PRKCA 2319/4885PRKD3 1382/4885PRKCG 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.